Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

Human Pathology

Volumn 39, Issue 7, 2008, Pages 1050-1058

  Xerri, Luc ^a,b,c   Chetaille, Bruno ^a,b,c   Seriari, Nacer ^b   Attias, Coralie ^a   Guillaume, Yves ^b   Arnoulet, Christine ^a   Olive, Daniel ^b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Angioimmunoblastic T cell lymphoma; Chronic lymphocytic leukemia; Immunohistochemistry; Non Hodgkin lymphoma; PD 1; PD L1, PD L2

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1; TUMOR MARKER;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER GRADING; CELL CLONE; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; IMMUNOBLASTIC LYMPHADENOPATHY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; TUMOR MARKERS, BIOLOGICAL;

EID: 45049087313     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.11.012     Document Type: Article

References (24)

1. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
2. Riley J.L., and June C.H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105 (2005) 13-21
3. Zha Y., Blank C., and Gajewski T.F. Negative regulation of T-cell function by PD1. Crit Rev Immunol 24 (2004) 229-237
4. Keir M.E., Latchman Y.E., Freeman G.J., and Sharpe A.H. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 175 (2005) 7372-7379
5. Brown J.A., Dorfman D.M., Ma F.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170 (2003) 1257-1266
6. Keir M.E., Liang S.C., Guleria I., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203 (2006) 883-895
7. Okazaki T., and Wang J. PD1/PD-L pathway and autoimmunity. Autoimmunity 38 (2005) 353-357
8. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
9. Freeman G.J., Wherry E.J., Ahmed R., and Sharpe A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203 (2006) 2223-2227
10. Chtanova T., Tangye S.G., Newton R., et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 173 (2004) 68-78
11. Dorfman D.M., Brown J.A., Shahsafaei A., and Freeman G.J. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 30 (2006) 802-810
12. Iwai Y., Okaszaki T., Nishimura H., Kawasaki A., Yagita H., and Honjo T. Microanatomical localization of PD-1 in human tonsils. Immunol Lett 83 (2002) 215-220
13. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., and Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006) 3639-3646
14. Olive D., Raymond J., Dubreuil P., Charmot D., Jacques Y., and Mawas C. Anti-interleukin 2 receptor monoclonal antibodies. Respective role of epitope mapping and monoclonal antibody-receptor interactions in their antagonist effects on interleukin 2-dependent T cell growth. Eur J Immunol 16 (1986) 611-616
15. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France 189-235
16. Ballester B., Ramuz O., Gisselbrecht C., et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 25 (2006) 1560-1570
17. Xerri L., Devilard E., Hassoun J., Olive D., and Birg F. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J Pathol 183 (1997) 182-187
18. Garrone P., Neidhardt E.M., Garcia E., Galibert L., van Kooten C., and Banchereau J. Fas ligation induces apoptosis of CD40 activated human B-lymphocytes. J Exp Med 182 (1995) 1265-1273
19. Jaksic O., Paro M.M., Kardum Skelin I., Kusec R., Pejsa V., and Jaksic B. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 103 (2004) 1968-1969
20. Soma L.A., Craig F.E., and Swerdlow S.H. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 37 (2006) 152-159
21. Blank C., Gajewski T.F., and Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54 (2005) 307-314
22. Hirano F., Kaneko K., Tamura H., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (2005) 1089-1096
23. Iwai Y., Terawaki S., and Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17 (2005) 133-144
24. Geng H., Zhang G.M., Xiao H., et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 118 (2006) 2657-2664